Endovascular Treatment of Thoracic Aortic Disease (EVOLVE Aorta)
Sponsor: Massachusetts General Hospital
Listed as NCT00583817, this NA trial focuses on Aortic Arch; Aneurysm, Dissecting and Aortic Dissection and remains ongoing. Sponsored by Massachusetts General Hospital, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Enrolling By Invitation NA
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation NA
-
Mar 2022 — Jul 2024 [monthly]
Enrolling By Invitation NA
-
Mar 2021 — Mar 2022 [monthly]
Enrolling By Invitation NA
-
Jan 2021 — Mar 2021 [monthly]
Enrolling By Invitation NA
▶ Show 8 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Enrolling By Invitation NA
-
Feb 2020 — Mar 2020 [monthly]
Enrolling By Invitation NA
-
Apr 2019 — Feb 2020 [monthly]
Enrolling By Invitation NA
-
Nov 2018 — Apr 2019 [monthly]
Enrolling By Invitation NA
Status: Recruiting → Enrolling By Invitation
-
Jun 2018 — Nov 2018 [monthly]
Recruiting NA
-
Apr 2017 — Jun 2018 [monthly]
Recruiting NA
Phase: PHASE1 → NA
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- Matthew Eagleton
For direct contact, visit the study record on ClinicalTrials.gov .